New Drug Approved for Early Lung Cancer

In China, AstraZeneca's drug Tagrisso has been approved for early stage lung cancer treatment. China's National Medical Products Administration (NMPA) approved the drug as an adjuvant therapy for early-stage lung cancer patients with a mutation of the EGFR gene, AstraZeneca said. More than a third of the world's lung cancer patients are in China and among those with non-small cell lung cancer (NSCLC), approximately 40 per cent have tumours with an EGFR mutation. "The expedited ...